Compare Hormel Foods Corp (HRL) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hormel Foods Corp vs Recursion Pharmaceuticals Inc — how do they compare? Hormel Foods Corp trades at $24.36 (market cap $13.37B), while Recursion Pharmaceuticals Inc trades at $3.36 (market cap $1.81B). The key difference: Hormel Foods Corp is far larger — about 7.4× Recursion Pharmaceuticals Inc's market cap, and Hormel Foods Corp pays a 4.81% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| HRL | RXRX | |
|---|---|---|
Market Cap | $13.37B | $1.81B |
Sector | Consumer Staples | Health |
52-Week High | $29.25 | $6.79 |
52-Week Low | $19.74 | $2.84 |
Enterprise Value | $15.37B | $1.33B |
Dividend Yield | 4.81% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Hormel Foods Corp
Hormel Foods is a protein-focused branded food company. Its brands include its namesake Hormel, Spam, Jennie-O, Dinty Moore, Applegate, Wholly Guacamole, and Skippy. The vast majority of the company's revenue is U.S.-based: 64% U.S. retail, 28% U.S. food service, and 8% international. By product type, in fiscal 2021, 23% of revenue was shelf-stable foods, 18% was poultry (branded and commodity), 55% was other perishable food, and 3% was other, primarily nutritional products. The company holds the number-one market position in shelf-stable meat, shelf-stable ready meals, pepperoni, natural/organic deli meat, and guacamole and the number-two position in turkey, bacon, chilled ready meals, and peanut butter.
Read more on HRL →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
